US FDA’s denial of emergency use authorisation for Covaxin comes on top of Bharat Biotech’s delay in submitting Phase 3 trial data to WHO. BB’s partner Ocugen is now pinning its hopes on Canada’s regulators....
from Times of India Opinion https://ift.tt/3vmHLay
No comments:
Post a Comment